Alteration of stomach microbiota compositions in the progression of gastritis induces nitric oxide in gastric cell

TIANYI DONG1,2, QIANG FENG3, FENGYAN LIU4, LAP KAM CHANG1, XIANGYU ZHOU1, MINGYONG HAN2, XINGSONG TIAN2, NING ZHONG4 and SHILI LIU1

1Department of Medical Microbiology, School of Medicine, Shandong University, Jinan, Shandong 250012; 2Department of Breast Thyroid Surgery, Shandong Provincial Hospital, Shandong University; 3Department of Human Microbiome, School of Stomatology, Shandong University, Shandong Provincial Key Laboratory of Oral Tissue Regeneration, Jinan, Shandong 250021; 4Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China

Received November 21, 2016; Accepted March 29, 2017

DOI: 10.3892/etm.2017.4373

Abstract. Atrophic gastritis is considered to be an antecedent to intestinal metaplasia and gastric cancer. A previous study identified Helicobacter pylori was absent at the severe atrophic gastritis stage, and alterations in the gastric microbial composition resembled those in gastric cancer. To explore the role of the bacteria absence of H. pylori in gastric carcinogenesis, in the current study, we compared the microbiota of clinically collected H. pylori-free gastric fluids from 30 patients with non-atrophic gastritis (N) and 22 patients with severe atrophic gastritis (S). We estimated the bacterial loads in the N and S groups by colony counting in culture agar as well as by measuring the concentration of the extracted DNA. The results showed a significant increase in bacterial load in patients with atrophic gastritis in comparison to non-atrophic gastritis. Then, we analyzed the microbial communities of the gastric fluids from all 52 patients using high-throughput sequencing of 16S rRNA amplicons. The Chao 1, Shannon and Simpson diversity indexes demonstrated that the bacterial richness and diversity were not significantly different between the N and S groups. Further analysis showed that all the higher taxonomic categories were significantly different between the N and S groups. To assess the effects of the metabolic products of Prevotella spp. on gastric cell physiology, we treated the human gastric epithelial cell line AGS with acetic acid and monitored nitric oxide (NO) production. The results showed that acetic acid at low concentrations (0.5 and 5 µM) significantly inhibited AGS cells to secrete NO compared to phosphate buffer saline-treated control cells. These results suggest that the microbiota in non-atrophic gastritis may influence gastric epithelial cell physiology.

Introduction

Gastric cancer is one of the most common malignant tumors. It accounts for about 10% of all invasive cancers and is the second leading cause of cancer deaths worldwide (1). Although the incidence of gastric cancer in the west had declined, it remains the most common type of cancer in Asia. In China, the total number of cases and deaths from gastric cancer have increased concomitant with huge ongoing demographic changes (2,3), resulting in an urgent need to find more effective diagnostic methods and treatments.

The human stomach harbors a large number of bacteria including Helicobacter pylori (4,5); these microbial organisms collectively compose the microbial community called the microbiota. Previous studies have shown that bacterial factors play an important role in the development of gastric cancer (5,6). Gastric cancer develops from a multifactorial, multistep inflammatory process, progressing through the stages of superficial gastritis, atrophic gastritis, intestinal metaplasia, and dysplasia before the development of gastric cancer (7). At the atrophic gastritis stage, the secretion of essential substances such as hydrochloric acid, pepsin, and intrinsic factor are impaired, resulting in a neutralized stomach environment. In turn, many other bacterial species can colonize the new environment leading to gastric microbiota overgrowth as the gastritis progress and low acid production (8,9). Atrophic gastritis is considered to be an antecedent to intestinal metaplasia and gastric cancer (10,11), thus, exploring the bacterial
factors that propel the progress of atrophic gastritis may be helpful for elucidating the mechanisms underlying gastric cancer development.

In previous studies, infection with *H. pylori* was reported to closely correlate with the other bacteria present in stomach (12), and clinical observations have found that atrophic gastritis without *H. pylori* is more likely to develop into gastric cancer than cases with *H. pylori*, an observation that has been supported by animal studies. Lee et al. also showed that intervention with antimicrobial therapies delayed the onset of gastric cancer in transgenic mice irrespective of *H. pylori* infection status (8). Moreover, other research has shown that feeding germ-free transgenic mice with artificial microbiota accelerated the occurrence of cancer (6). Noticeably, a study by Engstrand and Lindberg found that the changes in the microbiota in individuals with atrophic gastritis resemble those seen in gastric cancer (5). Thus, the absence of *H. pylori* in atrophic gastritis may play a crucial role in gastric carcinogenesis; thus, the alterations in the composition of gastric microbiota and its interaction with host cells require further studies.

However, there has been little study on the characterization of the absence of *H. pylori* in the progress of gastritis. In the current study, we investigated the variation in gastric microbiota using gastric fluids from 30 patients with non-atrophic gastritis (N) and 22 patients with chronic atrophic gastritis (S). Our results suggest that the microbiota in gastric fluids might influence gastric epithelial cell physiology and gastric carcinogenesis.

**Materials and methods**

*Patient samples collection and cell culture.* Gastric fluids newly extracted from 30 non-atrophic gastritis and 22 atrophic gastritis patients by endoscopy were obtained from Qilu Hospital of Shandong University (Jinan, China). All patients gave their informed consent prior to their inclusion in the study. The gastric fluids were kept at -80°C and used for subsequent analysis. All studies were reviewed and approved by the Ethic Committee of Shandong University (Jinan, China). Gastric adenocarcinoma cell line AGS cells were maintained in our laboratory. AGS cells were cultured in Ham's F-12 medium (HyClone, Logan, UT, USA) supplemented with 10% FCS and 1% penicillin-streptomycin. BGC-823 cells were cultured in RPMI-1640 (Life Technologies, Carlsbad, CA, USA) supplemented with 10% FCS (Tianhang Co., Ltd., Hangzhou, China) and 1% penicillin-streptomycin.

**Sequencing method**

*Extraction of genome DNA.* Total genome DNA from samples was extracted using CTAB/SDS method. DNA concentration and purity was monitored on 1% agarose gels. According to the concentration, DNA was diluted to 1 ng/µl using sterile water.

*Amplon generation.* Primer: 16S V4: 515F-806R, 18S V4: 528F-706R, 18S V9: 1380F-1510R, ITS1: ITS1FITS2. 16S/18S rRNA genes were amplified used the specific primer with the barcode. All PCR reactions were carried out in 30 µl reactions with 15 µl of Phusion® High-Fidelity PCR Master Mix (New England Biolabs, Ipswich, MA, USA); 0.2 µM of forward and reverse primers, and about 10 ng templates DNA. Thermal cycling consisted of initial denaturation at 98°C for 1 min, followed by 30 cycles of denaturation at 98°C for 10 sec, annealing at 50'C for 30 sec, and elongation at 72°C for 30 sec. Finally 72°C for 5 min.

*PCR products quantification and qualification.* Mix same volume of 1X loading buffer (contained SYBR-Green) with PCR products and operate electrophoresis on 2% agarose gel for detection. Samples with bright main strip between 400-450 bp were chosen for further experiments.

*PCR products mixing and purification.* PCR products were mixed in equidensity ratios. Then, mixture PCR products was purified with GeneJET Gel Extraction Kit (Thermo Scientific).

*Library preparation and sequencing.* Sequencing libraries were generated using NEB Next Ultra™ DNA Library Prep kit for Illumina (New England Biolabs) following manufacturer's recommendations and index codes were added. The library quality was assessed on the Qubit® 2.0 Fluorometer (Thermo Scientific) and Agilent Bioanalyzer 2100 system. At last, the library was sequenced on an Illumina MiSeq platform and 250/300 bp paired-end reads were generated.

*Data analysis.* Paired-end reads from the original DNA fragments were merged by using FLASH-a very fast and accurate analysis tool which is designed to merge paired-end reads when there are overlaps between reads1 and reads2. Paired-end reads was assigned to each sample according to the unique barcodes. Sequences were analyzed using QIIME software package (Quantitative Insights Into Microbial Ecology), and in-house Perl scripts were used to analyze alpha-(within samples) and beta-(among samples) diversity. First, reads were filtered by QIIME quality filters. Then we use pick_de_novo_otus.py to pick operational taxonomic units (OTUs) by using OTU table. Sequences with ≥97% similarity were assigned to the same OTUs. We pick a representative sequences for each OTU and use the RDP classifier to annotate taxonomic information for each representative sequence. In order to compute Alpha Diversity, we rarify the OTU table and calculate three metrics: Chao1 estimates the species abundance; Observed Species estimates the amount of unique OTUs found in each sample, and Shannon index. Rarefaction curves were generated based on these three metrics. QIIME calculates both weighted and unweighted unificr, which are phylogenetic measures of beta diversity.

*RNA extraction and quantitative real-time PCR (QRT-PCR).*

Total cellular RNA was extracted with TRIzol (Life Technologies) according to the protocol provided by the manufacturer. First-strand cDNA was synthesized from 1 µg total cellular or tissue RNA using the RevertAid™ First Strand cDNA Synthesis kit (Thermo Fisher Scientific, Waltham, MA, USA) with random primers. Then cDNA was amplified for quantitative real-time PCR, the specific primers used were as follows: for human nitric oxide synthase 2 (NOS2) forward primer 5'-GTTCCTCAAGGCAGGTCTCTC-3' and reverse primer 5'-GCAGGTCCTTTGATGCTTATC-3';
Statistical analyses. All experiments were repeated at least three times and the data were expressed as mean ± standard deviation (SD). The differences between the three groups were compared using the Student’s t-test and P<0.05 was considered statistically significant.

Results

Characteristics of the study subjects. From the data obtained, the baseline characteristics of the patients in the N and S groups were compared (Table I). In terms of the degree of atrophy, there was an obvious difference in the degree of inflammation and damage in endoscopy between the N and S groups (Fig. 1A and B). However, there was no significant difference in body mass index between these two groups (Fig. 1C, P=0.73).

Increased bacterial load in chronic atrophic gastritis. To compare the total bacterial number in gastric fluids, 5 ml of each sample fluid was centrifuged and the precipitate was used for spreading plate and microaerobic culture in blood agar. The amount of cultivable bacteria of N and S patients was calculated as 13.7 and 435 colonies per 5 ml gastric fluid, respectively. Student’s t-test showed significant difference (Fig. 2A, P<0.05). This result was verified by the amount of bacterial DNA extracted from the gastric fluids (Fig. 2B, P=0.0418). Compared with non-chronic gastritis, the bacterial load in chronic atrophic gastritis was significantly increased, suggesting that there was an association between the amount of bacteria and the severity of the gastritis.

Diversity of gastric microbiota. The microbial communities of the gastric fluids from the 52 patients were analyzed using high-throughput sequencing of 16S rRNA amplicons. Good’s coverage, an index representing read coverage or depth was calculated, and the results showed that the coverage was more than 0.99 in both groups with no statistical significance between the two groups (P=0.5403) (Fig. 3A). To evaluate the bacterial diversity between the two groups, the Chao 1-estimated richness as well as Shannon’s and Simpson’s diversity indices were compared. As shown in Fig. 3B-D, the Chao 1 value of the microbiota in atrophic gastritis was similar to that in non-atrophic gastritis (N group=339.82, S group=340.72; P=0.9749) (Fig. 3B). Shannon’s and Simpson’s diversity indices in atrophic gastritis (4.70 and 0.88, respectively) were slightly lower than those in non-atrophic gastritis (4.96 and 0.93, respectively). However, these differences were not statistically significant (P=0.2112 for Shannon’s and 0.0709 for Simpson’s diversity index) (Fig. 3C and D). These results demonstrated that the diversity indices were not significantly different between the two groups.

The structure of the microbiota communities was explored by PCA. The results showed that the microbiota from the N group tended to cluster together, whereas samples from S group were scattered in the PCA plot (Fig. 3E). This suggests that the structure of the microbial communities in atrophic gastritis was phylogenetically diversified.

Compositional analysis of gastric microbiota. Compositional analysis showed that the entire dataset was clustered into 27 phyla, 61 classes, 177 families and 292 genera, respectively. The most representative phylum was Proteobacteria (representing an average of 34.9% for the N group and 40.8% for the S group of all phyla), followed by Bacteroidetes (32.8 vs. 23.3%, respectively), Firmicutes (14.4 vs. 20.9%, respectively), Fusobacteria (11.1 vs. 8.8%, respectively) and Actinobacteria (2.81 vs. 2.71%, respectively). Although the most predominant phylum varied between individuals, only one phylum, Bacteroidetes, was enriched in the non-atrophic gastritis group and had significant difference to the atrophic gastritis groups (P=0.013, Fig. 4A). The proportion of Firmicutes, Fusobacteria, Actinobacteria and Proteobacteria were varied in the two groups without statistical significances (Fig. 4B-E).

Similar to the phyla level, only one genus of bacteria, Prevotella, was accumulated in the N gastritis group at the genus level, and its abundance was significantly different from that of the S group (Fig. 4F). Prevotella was the major genus of the phylum Bacteroidetes, the class Bacteroidia, the order Bacteroidales, and the family Prevotellaceae. All the higher taxonomic categories besides the phylum showed significant differences between the N and S groups (Fig. 4G-I). In an analysis at the species level, we found that the genus Prevotella of the stomach microbiota was composed of P. melaninogena (making up an average of 9.17% for the N group and 6.95% for the S group of all species); P. nancei (2.55 vs. 1.48%, respectively); P. pallens (2.27 vs. 1.60%, respectively); H. pylori (2.67% vs. 4.13%, respectively); H. pylori (2.67% vs. 4.13%, respectively); and H. pylori (2.67% vs. 4.13%, respectively).
respectively); *P. tannerae* (1.59 vs. 1.06%, respectively); *P. intermedia* (0.92 vs. 0.84%, respectively); *P. nigrescens* (0.27 vs. 0.18%, respectively) and *P. copri* (0.038 vs. 0.011%, respectively). Collectively, these species represented more than 92.4% of the species in the *Prevotella* genus in the tested gastric fluids.

Acetic acid, the major metabolic product of *Prevotella*, decreases NO secretion in AGS cells. The major metabolic products of *Prevotella* spp. are acetic acid, butane diacid and small amount of isobutyric acid, isovaleric acid and lactic acid. To assess effects of these metabolic products of *Prevotella* spp. in gastric fluids on stomach epithelial cell physiology, we treated the human gastric epithelial cell line AGS with acetic acid and monitored NO production. As shown in Fig. 5A, the AGS cells incubated with low concentrations of acetic acid (0.5 and 5 µM) had significantly decreased NO secretion in culture media compared to phosphate buffered saline-treated control cells. This result was verified by QRT-PCR of NOS2 (Fig. 5B). These results suggested that *Prevotella* spp. in gastric fluids might impact human cell physiology.

**Discussion**

The human microbiota consists of approximately 100 trillion microbial cells, that outnumber the human cells by 10
In healthy individuals, the gut microbiome functions as a symbiont that can offer protection from invading pathogens and prevent tumorigenesis (13). However, this commensal community exists in a careful balance that, if disrupted, enters dysbiosis and can contribute to host disease processes, including the development of cancer (14-18). The stomach harbors a large number of bacteria, and especially at the atrophic gastritis stage, the neutralized stomach can be colonized by many other bacterial species in addition to H. pylori (4). A study by Engstrand and Lindberg found that gastric microbiota overgrowth with the progress of gastritis to severe atrophic gastritis which had low acid production and no H. pylori present. They also discovered that the changes in the microbiota in individuals with atrophic gastritis resembled those seen in gastric cancer (5). Thus, it has been postulated that some microbial species colonizing the stomach may further promote gastritis, genotoxic damage and the progression to gastric cancer (6,19,20), though there is considerable variation in the most abundant bacterial species between individuals.

The stomach plays an important role in maintaining gastrointestinal health, acting as a barrier against ingested infectious disease agents of the lower gastrointestinal tract (21). A previous study found that there was no statistical significant difference between the operational taxonomic units (OTUs) of gastric fluid and mucosa, and the mean of the OTUs was higher in gastric fluid than that in mucosa. Generally, the gastric fluid samples showed higher diversity compared to gastric mucosa samples (22). Moreover, gastric fluid is easy to obtain and the detection of H. pylori is more accurate than in

Figure 3. Diversity of gastric microbiota. (A) Results showed that the Goods coverage was both more than 0.99 and no statistical significance between the two groups. (B) The Chao 1, (C and D) Shannon's and Simpson's diversity indices in atrophic gastritis were not statistically significant different to that in non-atrophic gastritis. The PCA results showed the microbiota from the N group tended to cluster together, whereas samples from S group were scattered in (E) the PCA plot. All the analysis of microbiota were performed as described in Materials and methods.
Figure 4. Comparison of gastric microbiota in N and S groups at various taxonomic levels. (A) Phylum Bacteroidetes was enriched in the non-atrophic gastritis group and had significant difference to the atrophic gastritis groups. (B-E) The proportion of Firmicutes, Fusobacteria, Actinobacteria and Proteobacteria were varied in the two groups without statistical significances. *Prevotella* was accumulated in the N gastritis group at the genus level (F, *P*=0.05). (G) The higher taxonomic categories Bacteroidia (*P*=0.012), (H) Bacteroidales (*P*=0.012) and (I) Prevotellaceae (*P*=0.049) showed significant differences between the N and S groups. *P*<0.05.

Figure 5. Acetic acid increases NO secretion in AGS cells. (A) The AGS cells incubated with low concentrations of acetic acid (0.5 and 5 µM) had significantly increased NO secretion in culture media compared to phosphate buffered saline-treated control cells. (B) The result was verified by QRT-PCR of NOS2. QRT-PCR was performed as described in Materials and methods. *P*<0.05.

Gastric mucosa, in which the amount of *H. pylori* detected may vary as the sampling location changes. Thus, in the current study, we used gastric fluids from *H. pylori*-negative gastritis patients for microbiota analysis.
*H. pylori* is the best known bacterial species that thrives in the acidic environment of the normal stomach. Inflammatory responses to *H. pylori* are thought to result in the destruction of cells that secrete acid into the stomach, leading to a condition known as atrophic gastritis. At the atrophic gastritis stage, gastric microbiota overgrowth and severe atrophic gastritis with low acid production occurs without *H. pylori* present. Clinical parameters for estimating the severity of atrophic gastritis include the degree and range of inflammation, the pH of the gastric fluids and *H. pylori* infection status. In fact, the existence of *H. pylori* is also related to the degree of inflammation and the pH of gastric fluids. However, the composition and function of microbiota absence of *H. pylori* remain poorly understood. Given that gastric microbes other than *H. pylori* are potentially linked to the development of gastric cancer. In the present study, we investigated the variation of gastric microbiota using gastric fluids from 30 patients with non-atrophic gastritis and 22 patients with chronic atrophic gastritis.

*Prevotella* spp. is a strictly anaerobic, Gram-negative bacterium that is non-spore forming. It does not reduce urease or nitrogen. When this organism grows on blood-containing media, it produces acid in the medium and resists acidic environments. *Prevotella* spp., i.e., *P. melaninogenica*, enrichment may contribute to the pH of the stomach becoming more acidic than in non-atrophic gastritis. Additionally, *Prevotella* spp. growth is inhibited by the presence of iron. The gastric mucosa is damaged at the atrophic gastritis stage, resulting in the leakage of tissue fluid and blood into the gastric fluids, which in turn, may result in higher iron content than in non-atrophic gastritis. Therefore, *Prevotella* spp. growth is suppressed in atrophic gastritis group.

NO is a short-lived, endogenously produced gas that acts as a signaling molecule in the body. It is synthesized by NOS and serves as a key signaling molecule in various physiological processes. Excessive and unregulated NO synthesis has been linked to contribute pathological conditions including cancer. Overexpression of NOS2 with high levels of NO generation provides a plausible link between inflammation and cancer initiation, progression, and promotion. Indeed, there is substantial evidence implicating NO in cancer as an endogenous mutagen (23), an angiogenesis factor (24), an enhancer of protooncogene expression (25), and an inhibitor of apoptosis (26). In a study by Feng *et al*, when lesions progressed from normal to chronic gastritis and finally to gastric cancer, positive immunostaining for p53, NOS2, and vascular endothelial growth factor (VEGF) was found to be significantly increased (27). That study also demonstrated that the positive immunostaining rates of NOS2 were correlated well with gastric cancer lymph node metastasis. NOS2 gene expression and NO production are regulated by the transcription factors NFκB, the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway, and c-Jun NH2-terminal kinase (JNK)-activator protein-1 (AP-1) pathways (28), whereas they are downregulated by steroids, transforming growth factor (TGF)-β, the heat shock response element, and p53 (29). A previous report showed that Short-Chain Fatty Acids (SCFAs) decreased immunoreactivity and the number of COX-2, NFκB and iNOS positive cells in colon tissue (30). Moreover, another report demonstrated that SCFAs suppressed NFκB and the production of inflammatory cytokines such as IL-6 and TNF-α, but increased IL-10 secretion from macrophages (31). All these findings suggest a role of NO in the initiation and progression of gastric cancer.

16S rRNA sequencing method has limitation, because it is unable to distinguish between living and dead bacteria. Although conventional culture could provide a complementary result, most of the gastrointestinal bacteria is uncultivable, and that bacteria with rapid growth rate would cover the plate over the slow growing bacteria, making culture method unsuitable for the present study. Due to 16S rRNA sequencing provides a complete view of the overall microbiota, our study is valuable for assessing the differences in microbiota composition from various aspects using a large number of samples. Further studies for functional role of gastric microbiota on gastric carcinogenesis such as metabolite profiling of *Prevotella* spp. mechanism studie using gnotobiotic mice are warranted.

Acknowledgements

We gratefully acknowledge the financial support from The National Natural Science Foundation of China (81272351), The Fundamental Research Funds of Shandong University (2015JC010), Project of Medical and Health Technology Development Program in Shandong province (Grant no. 2014ws0349) and Open Research Fund of State Key Laboratory of Environmental Chemistry and Ecotoxicology (KF2014-08).

References

1. Roder DM: The epidemiology of gastric cancer. Gastric Cancer 5 Suppl 1: S5-S11, 2002.
2. Yang L, Parkin DM, Ferlay J, Li L and Chen Y: Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 14: 243-250, 2005.
3. Yang L, Parkin DM, Li LD, Chen YD and Bray F: Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br J Cancer 90: 2157-2166, 2004.
4. Wang LL, Yu XJ, Zhan SH, Jia SJ, Tian ZB and Dong QF: Participation of microbiota in the development of gastric cancer. World J Gastroenterol 20: 4948-4952, 2014.
5. Engstrand L and Lindberg M: Helicobacter pylori and the gastric microbiota. Best Pract Res Clin Gastroenterol 27: 39-45, 2013.
6. Lertpiriyapong K, Whary MT, Muthupalani S, Loefgren JL, Gamanzon ER, Feng Y, Ge Z, Wang TC and Fox JD: Gastric colonisation with a restricted commensal microbiota replicates the promotion of neoplastic lesions by diverse intestinal microbiota in the *helicobacter pylori* INS-GAS mouse model of gastric carcinogenesis. Gut 63: 54-63, 2014.
7. Correa P: Human gastric carcinogenesis: A multistep and multifactorial process-first american cancer society award lecture on cancer epidemiology and prevention. Cancer Res 52: 6735-6740, 1992.
8. Lee CW, Rickman B, Rogers AB, Muthupalani S, Takaishi S, Yang P, Wang TC and Fox JD: Combination of sulindac and anti-microbial eradication of *Helicobacter pylori* prevents progression of gastric cancer in hypergastrinemic INS-GAS mice. Cancer Res 69: 8166-8174, 2009.
9. Mowat C, Williams C, Gillen D, Hossack M, Gilmour D, Carswell A, Wirz A, Preston T and McColl KE: Omeprazole, *Helicobacter pylori* status, and alterations in the intragastric milieu facilitating bacterial N-nitrosation. Gastroenterology 119: 339-347, 2000.
10. Joo YE, Park HK, Mueng DS, Baik GH, Shin JE, Seo GS, Kim GH, Kim HU, Kim HY, Cho SI and Kim N: Prevalence and risk factors of atrophic gastritis and intestinal metaplasia: A nationwide multicenter prospective study in Korea. Gut Liver 7: 303-310, 2013.
11. Park YH and Kim N: Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. J Cancer Prev 20: 25-40, 2015.
12. Cao L and Yu J: Effect of helicobacter pylori infection on the composition of gastric microbiota in the development of gastric cancer. Gastrointest Tumors 2: 14-25, 2015.

13. Yang Y, Wang X, Huyck T, Moore DR, Lightfoot SA and Huyck MM: Colon macrophages polarized by commensal bacteria cause colitis and cancer through the bystander effect. Transl Oncol 6: 596-606, 2013.

14. Candela M, Turroni S, Biagi E, Carbonero F, Rampelli S, Fiorentini C and Brigidi P: Inflammation and colorectal cancer, when microbiota-host mutualism breaks. World J Gastroenterol 20: 908-922, 2014.

15. Dicksved J, Lindberg M, Rosenquist M, Enroth H, Jansson JK and Engstrand L: Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls. J Med Microbiol 58: 509-516, 2009.

16. Jobin C: Colorectal cancer: Looking for answers in the microbiota. Cancer Discov 3: 384-387, 2013.

17. Schwabe RF and Jobin C: The microbiome and cancer. Nat Rev Cancer 13: 800-812, 2013.

18. Bik EM, Eckburg PB, Gill SR, Nelson KE, Purdom E, Francois F, Perez-Perez G, Blaser MJ and Relman DA: Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci USA 103: 732-737, 2006.

19. Martinen TC, Bergh K and Waldum H: Gastric juice: A barrier against infectious diseases. Basic Clin Pharmacol Toxicol 96: 94-102, 2005.

20. Sung J, Kim N, Kim J, Jo HJ, Park JH, Nam RH, Seok YJ, Kim YR, Lee DH and Jung HC: Comparison of gastric microbiota between gastric juice and mucosa by next generation sequencing method. J Cancer Prev 21: 60-65, 2016.

21. Wink DA, Kasprzak KS, Maragosd CM, Elespru RK, Misra M, Dunams TM, Cebula TA, Koch WN, Andrews AW, Aleen JS, et al: DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science 254: 1001-1003, 1991.

22. Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, Rhodes P, Westmore K, Emson PC and Moncada S: Role of nitric oxide in tumor growth. Proc Natl Acad Sci USA 92: 4392-4396, 1995.

23. Ambu S, Ogunsaha G, Merriam WG, Bennett WP, Biliam TR and Harris CC: Up-regulation of inducible nitric oxide synthase expression in cancer-prone p53 knockout mice. Proc Natl Acad Sci USA 95: 8823-8828, 1998.

24. Li J, Biliam TR, Talanian RV and Kim YM: Nitric oxide reversibly inhibits seven members of the caspase family via S-nitrosylation. Biochem Biophys Res Commun 240: 419-424, 1997.

25. Feng CW, Wang LD, Jiao LH, Liu B, Zheng S and Xie XJ: Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: Correlation with clinical features. BMC Cancer 2: 8, 2002.

26. Park JS, Lee JH, Lee JH, Kim WK and Kim HS: Anti-inflammatory effects of short chain fatty acids in IFN-gamma-stimulated RAW 264.7 murine macrophage cells: Involvement of NF-kappaB and ERK signaling pathways. Int Immunopharmacol 7: 70-77, 2007.